- Conditions
- Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Cancer
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy
- Radiation · Drug
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- Female only
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 439
- States / cities
- Auburn, California • Berkeley, California • Burbank, California + 292 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 1,787
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Nivolumab, Cisplatin, Cetuximab, IMRT
- Drug · Radiation
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more
- Conditions
- Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
- Interventions
- Cisplatin, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Fullerton, California • La Jolla, California + 33 more
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
- Interventions
- Modified GCN+TTF treatment
- Combination Product
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- cisplatin, cyclophosphamide, vincristine sulfate, etoposide, therapeutic conventional surgery, 3-dimensional conformal radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 3 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Sirolimus, Cystectomy
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
- Conditions
- Laryngeal Squamous Cell Carcinoma
- Interventions
- Cisplatin, Epinephrine injection, Laryngeal Biopsy, Endoscopic Surgery
- Drug · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Head and Neck Neoplasms
- Interventions
- Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
- Biological · Radiation · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 68
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
- Conditions
- Oropharynx Cancer
- Interventions
- therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment, intensity-modulated radiation therapy, Cisplatin, Carboplatin
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- Heath Skinner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Solid Tumors, Bladder Cancer
- Interventions
- Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Anal Canal Carcinoma, Stage IIIB Anal Canal Cancer, Stage IV Anal Canal Cancer
- Interventions
- Capecitabine, Carboplatin, Cisplatin, Fluorouracil, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Interventions
- Doxorubicin Hydrochloride, Cisplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, docetaxel, 5-fluorouracil, surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 74
- States / cities
- Norwich, Connecticut • Aurora, Illinois • Chicago, Illinois + 51 more
- Conditions
- Head and Neck Cancer
- Interventions
- amifostine trihydrate, cisplatin, fluorouracil, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced/Metastatic Tumors
- Interventions
- Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more
- Conditions
- Advanced Solid Tumours
- Interventions
- AZD9150, Durvalumab, Cisplatin, 5-Flourouracil, Carboplatin, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 6
- States / cities
- Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
- Conditions
- HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, Oropharynx Cancer
- Interventions
- Transoral robotic surgery, Cisplatin - Dose Level 1, Cisplatin - Dose Level 2, Dose Level 1, Dose Level 2
- Procedure · Drug · Radiation
- Lead sponsor
- Nebraska Methodist Health System
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Interventions
- Cisplatin, Gemcitabine, ALT-801
- Drug · Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
- Interventions
- RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Gilbert, Arizona • Duarte, California • Irvine, California + 24 more
- Conditions
- Advanced Solid Tumors
- Interventions
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more
- Conditions
- Metastatic Osteosarcoma
- Interventions
- doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- SIR-Spheres microspheres (Yttrium-90 Microspheres), Gemcitabine, Cisplatin
- Device · Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina